WASHINGTON — Another preclinical study has added evidence that cannabidiol, or CBD, may have potential as an antibiotic, researchers said at ASM Microbe.
Prior research has shown that CBD, the main non-psychoactive component in cannabis, has activity against gram-positive bacteria, including resistant strains of Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecalis.
Last year, a study published in Communications Biology showed for the first time that CBD could also kill a subset of gram-negative bacteria, including Neisseria gonorrhoeae.
“We have a long-lasting